Can we select NSCLC patients for immune checkpoint therapy?

26 / 38

X
AVOID TOXICITIES IN
NON-RESPONDERS
Courtesy of Prof Besse Ferrara R, et al. WCLC 2017. Saâda-Bouzid E, et al. Ann Oncol. 2017; Champiat S, et al. Clin Cancer Res. 2017;
Who (not) to give?